4-(2H-tetrazol-5-yl)-2-[2-[[2-(2,2,2-trifluoroethoxy)phenyl]methyl]-1H-imidazol-5-yl]pyridine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(2H-tetrazol-5-yl)-2-[2-[[2-(2,2,2-trifluoroethoxy)phenyl]methyl]-1H-imidazol-5-yl]pyridine
• 化学式: C₁₈H₁₄F₃N₇O
• 分子量: 401.3
• InChiKey: PLWFPHWFYYEQQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• HISTONE DEMETHYLASE INHIBITORS
  申请人：Quanticel Pharmaceuticals Inc

  公开号：EP2969007A1

  公开（公告）日：2016-01-20
• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS D'HISTONE DÉMÉTHYLASE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2014151945A1

  公开（公告）日：2014-09-25

  The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.